Icosavax

company

About

Icosavax is focused on developing safe and effective vaccines against infectious diseases that address important unmet medical needs.

  • 11 - 50

Details

Last Funding Type
Series A
Last Funding Money Raised
$51M
Industries
Biotechnology,Health Care,Pharmaceutical
Founded date
Jan 1, 2017
Number Of Employee
11 - 50
Operating Status
Active

Icosavax is a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases. Icosavax’s VLP platform technology is designed to enable multivalent, particle-based display of complex viral antigens, which it believes will induce broad, robust, and durable protection against the specific viruses targeted. Icosavax’s pipeline includes vaccine candidates targeting respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Icosavax was formed in 2017 to advance the breakthrough VLP technology from the Institute for Protein Design at the University of Washington with the goal to discover, develop, and commercialize vaccines against infectious diseases.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$51M
Icosavax has raised a total of $51M in funding over 2 rounds. Their latest funding was raised on Oct 3, 2019 from a Series A round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Oct 3, 2019 Series A $51M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
Icosavax is funded by 1 investors. Sanofi are the most recent investors.
Investor Name Lead Investor Funding Round
Sanofi Series A